Tamoxifen

Tamoxifen (TAM) is a selective estrogen receptor modulator primarily used in the management of breast cancer, acting on estrogen receptors found in various tissues, including the breast and retina. Researchers primarily study tamoxifen for its efficacy in treating estrogen receptor-positive breast cancer and its associated side effects. Key findings indicate that tamoxifen can lead to retinal toxicity in a small percentage of patients, with incidence rates ranging from 0.9% to 12%, and that resistance to tamoxifen in breast cancer cells may be linked to mechanisms involving reactive oxygen species and ferroptosis. Current research is focused on understanding the long-term effects of tamoxifen, optimizing its therapeutic use, and identifying risk factors for adverse events, including thromboembolic complications. Clinical evidence suggests that while tamoxifen remains a cornerstone in breast cancer therapy, ongoing studies are essential to enhance patient safety and treatment outcomes.

Tamoxifen, also known by its trade name Nolvadex, is a synthetic selective estrogen receptor modulator (SERM) primarily used in the management of breast cancer. It is not an endogenous hormone but is chemically synthesized for therapeutic purposes. Tamoxifen belongs to the class of compounds known as triphenylethylenes and is administered orally. Researchers have extensively studied its effects on estrogen receptors, which are present in various tissues, including the breast, retina, and choroid. The primary physiological role of tamoxifen is to act as an antagonist of estrogen receptors in breast tissue, thereby inhibiting the growth of estrogen-dependent tumors. It is widely used in both the treatment and prevention of breast cancer, particularly in estrogen receptor-positive cases. Tamoxifen is also involved in research areas concerning its effects on other tissues, such as the retina, where it may cause retinopathy. The mechanism of action of tamoxifen involves binding to estrogen receptors, thereby blocking estrogen from binding and activating these receptors. This inhibition prevents the transcription of estrogen-responsive genes that promote cell proliferation. Tamoxifen also affects mitochondrial function by increasing reactive oxygen species, which can influence cancer cell survival. Pharmacokinetically, tamoxifen has a long half-life of approximately 5 to 7 days, allowing for once-daily dosing. It is metabolized in the liver by cytochrome P450 enzymes into active metabolites, including endoxifen. Tamoxifen is well absorbed orally, but its bioavailability is subject to first-pass metabolism. Clinically, tamoxifen is approved for use in the treatment of both early and advanced breast cancer, as well as for breast cancer chemoprevention. It is considered a prescription medication in many countries and is not classified as a controlled substance. Ongoing research continues to explore its optimal duration of use and its comparison with newer therapies such as aromatase inhibitors.

Tamoxifen acts primarily on estrogen receptors, particularly in breast tissue, where it functions as an antagonist, blocking estrogen from binding and activating these receptors. This action inhibits the transcription of estrogen-responsive genes, reducing cell proliferation and tumor growth. Additionally, tamoxifen influences mitochondrial function by increasing reactive oxygen species, which can affect cancer cell survival and resistance to therapy.

Tamoxifen (TAM) primarily acts as a selective estrogen receptor modulator (SERM), competitively inhibiting estrogen receptors (ER) in breast tissue, thereby blocking estrogen-mediated signaling pathways that promote tumor growth. Additionally, TAM can induce oxidative stress by increasing reactive oxygen species (ROS), which may enhance ferroptosis in sensitive breast cancer cells, while the upregulation of glutathione peroxidase 4 (GPX4) by RelB contributes to TAM resistance by inhibiting this cell death pathway. The full mechanism of TAM's action, particularly its effects on non-target tissues like the retina and its role in thromboembolic events, remains incompletely understood.

Current evidence is limited regarding the long-term effects of tamoxifen on retinal health, particularly the optimal screening methods for early detection of tamoxifen-induced retinopathy, which remains poorly defined. Further research is needed to clarify the mechanisms underlying tamoxifen resistance in breast cancer, particularly the role of ferroptosis and the RelB-GPX4 pathway, through larger randomized controlled trials that include diverse patient populations. Additionally, while thromboembolic risks associated with tamoxifen have been identified, further studies are necessary to determine the specific thromboembolic events that require enhanced surveillance and to validate the risk factors identified in real-world assessments.